GlassScriptPhysician profile
Molly Lynn Mudd
NPI 1518482298
$688.36
in general payments reported to CMS, 2019-2025
14 companies · $242 in 2025
The $242 reported for 2025 was more than what 80% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $274 · 2024: $173 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $164.25 | 2023-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $131.45 | 2023-2025 | Bexsero, Flulaval Quadrivalent, Penmenvy |
| Corium, LLC | $61.93 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $51.58 | 2023-2025 | |
| Cranial Technologies, INC | $47.50 | 2024-2025 | Doc Band |
| Tris Pharma INC | $44.79 | 2024-2025 | Dyanavel Xr |
| Biogen, INC. | $40.39 | 2023 | Spinraza |
| Sanofi-Aventis U.S. LLC | $31.02 | 2025 | |
| Merck Sharp & Dohme LLC | $28.18 | 2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Alk-Abello, INC | $20.12 | 2025 | Neffy |
| Neos Therapeutics, LP | $17.60 | 2023 | Adzenys Xr-Odt |
| Pfizer INC. | $16.99 | 2024 | |
| Vertical Pharmaceuticals, LLC | $16.56 | 2025 | Relexxii |
| Azurity Pharmaceuticals, INC. | $16.00 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.